Welcome to our dedicated page for Korro Bio news (Ticker: KRRO), a resource for investors and traders seeking the latest updates and insights on Korro Bio stock.
Korro Bio, Inc. (Nasdaq: KRRO) is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts that develops genetic medicines using RNA editing. News about Korro often centers on the progress of its lead candidate KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), updates from the Phase 1/2a REWRITE clinical trial, and regulatory milestones such as Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency.
Investors and observers following KRRO can expect coverage of Korro’s pipeline updates, including the nomination and advancement of KRRO-121, an RNA-editing GalNAc-conjugated candidate for hyperammonemia in urea cycle disorders and hepatic encephalopathy. Company communications also highlight its broader portfolio of GalNAc-conjugated liver-targeted programs and its efforts to apply the OPERA RNA editing platform to both rare and more prevalent diseases.
Additional Korro Bio news includes financial results, cash runway commentary, and restructuring actions such as workforce reductions intended to focus resources on clinical data generation and liver-targeted programs. The company’s collaboration and license agreement with Novo Nordisk A/S, and subsequent amendment establishing a 12‑month pause in research and development activities under that collaboration, are also key topics in recent updates.
Coverage frequently notes leadership and governance developments, including executive appointments, departures, and interim roles described in Korro’s SEC filings and press releases. For readers tracking KRRO, this news page aggregates announcements on clinical data, regulatory designations, business strategy, and corporate changes, providing a centralized view of Korro’s ongoing development as an RNA-editing biopharmaceutical company.
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, announced presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, October 6-9, 2024. The company will deliver one oral and two poster presentations.
The oral presentation, by Dr. Venkat Krishnamurthy, Senior VP and Head of Platform, will focus on KRRO-110, Korro's first development candidate for alpha-1 antitrypsin deficiency (AATD). This inherited disorder is caused by single nucleotide variants in the SERPINA1 gene.
The two poster presentations will cover:
- Purification of Human ADAR for evaluating oligo-directed RNA editing
- Using ADAR1 chimeric eCLIP to understand on-target and off-target behaviors of RNA editing oligonucleotides
Korro Bio (Nasdaq: KRRO) has announced a collaboration with Novo Nordisk to develop two therapeutic candidates using Korro's proprietary OPERA™ platform for RNA editing. The partnership, initially focusing on cardiometabolic diseases, has a total deal value of up to $530 million in upfront, development, and commercial milestone payments, plus tiered royalties and R&D funding.
The collaboration combines Novo Nordisk's expertise in cardiometabolic diseases with Korro's RNA editing technology to potentially address undruggable targets. Korro's OPERA platform aims to modify mRNA without altering DNA, offering a pharmacologically titratable approach to genetic medicine. Korro will advance up to two programs through preclinical development, after which Novo Nordisk may progress them to clinical studies.
Korro Bio (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, has announced its participation in two upcoming investor conferences. At the 2024 Cantor Global Healthcare Conference on September 17, COO Todd Chappell will engage in a fireside chat, while CFO Vineet Agarwal will attend investor meetings. At Chardan's 8th Annual Genetic Medicines Conference on September 30, CEO and President Ram Aiyar will participate in a fireside chat, with Agarwal also in attendance.
Both fireside chats will be webcast live and accessible through Korro's website, with replays available for 30 days post-event. These conferences provide Korro an opportunity to showcase its innovative approach to genetic medicine and engage with investors.
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company focused on RNA editing for rare and prevalent diseases, has announced significant changes to its Board of Directors. Dr. Katharine Knobil, an industry veteran with over 25 years of experience, has been appointed as an Independent Director. Dr. Knobil brings extensive expertise in clinical development and regulatory affairs, having held key positions at Agilent Technologies, Kaleido Biosciences, and GlaxoSmithKline.
Simultaneously, David Lucchino has stepped down from the Board. Dr. Ram Aiyar, CEO and President of Korro, expressed enthusiasm about Dr. Knobil's appointment, highlighting her valuable experience as the company advances its innovative pipeline. Dr. Knobil shared her excitement about joining Korro and contributing to the advancement of RNA editing technology.
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, announced its participation in several upcoming investor and scientific conferences in September 2024. These include:
1. 2024 Wells Fargo Healthcare Conference (Sept. 4): 1x1 investor meetings
2. RNA Leaders USA Congress (Sept. 5): Presentation on OPERA™ platform
3. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9): Company presentation
4. ISCTM 2024 Autumn Conference (Sept. 12): Session on neurophysiological markers
The H.C. Wainwright presentation will be webcast live and available for replay on Korro's website for 30 days.
Korro Bio (NASDAQ: KRRO) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Regulatory filing for KRRO-110 in alpha-1 antitrypsin deficiency (AATD) expected in H2 2024.
2. Preclinical data presented at ATS 2024 showed KRRO-110's ability to correct AAT protein, resulting in >70% M-AAT in circulation.
3. Q2 2024 ended with $187.8 million in cash, cash equivalents, and marketable securities.
4. Cash runway extended into H2 2026, funding KRRO-110 FIH trial completion and pipeline advancement.
5. Q2 2024 financial results: R&D expenses $17.1 million, G&A expenses $7.0 million, net loss $21.8 million.
6. Interim Phase 1/2 clinical trial readout for KRRO-110 in ZZ AATD patients expected in H2 2025.
Korro Bio has been added to the Russell 2000, Russell 3000, and Russell Microcap Indexes as part of the annual reconstitution effective July 1, 2024. This inclusion is based on market capitalization rankings determined by FTSE Russell. Korro Bio's CEO, Dr. Ram Aiyar, emphasized their commitment to advancing their drug candidate, KRRO-110, for Alpha-1 Antitrypsin Deficiency, with plans to file with regulatory agencies in the second half of 2024 and an interim data readout in the second half of 2025. The inclusion in these indexes is expected to enhance value for Korro's stakeholders.
Korro Bio (Nasdaq: KRRO) will participate in several significant investor and scientific conferences in June 2024.
CEO Ram Aiyar, Ph.D., and CFO Vineet Agarwal will present at the Jefferies Global Healthcare Conference on June 6 at 2:00 p.m. ET.
CMO Dr. Kemi Olugemo will discuss Korro's lead RNA editing oligonucleotide candidate, KRRO-110, for treating Alpha-1 Antitrypsin Deficiency at the 2024 Alpha-1 Foundation National Conference on June 8 at 11:20 a.m. ET.
Senior VP Venkat Krishnamurthy, Ph.D., will participate in the 5th Annual RNA Editing Summit on June 20, engaging in a roundtable discussion and giving a presentation on the OPERA platform and its clinical progress.
The Jefferies presentation will be webcast live, with a replay available for 30 days on Korro's website.
Korro Bio presented new preclinical data on KRRO-110 at the 2024 American Thoracic Society International Conference. The data demonstrated sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to over 60µM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model. Notably, KRRO-110 showed 35µM of M-AAT one week post the first dose, rising to 45µM of M-AAT by week 13. This data suggests KRRO-110's potential as a best-in-class therapeutic for AATD. Korro plans to submit a regulatory filing for a first-in-human study in the second half of 2024.
Korro Bio (Nasdaq: KRRO) reported its financial results for Q1 2024 and announced the appointment of Dr. Kemi Olugemo as Chief Medical Officer. Significant milestones include a $70 million private placement completed in April 2024, increasing cash reserves to $206 million. This funding extends Korro's cash runway into the second half of 2026. Pipeline progress includes plans for a regulatory filing for KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD), in the latter half of 2024. Interim readout for KRRO-110 is expected in H2 2025, with trial completion in 2026. Financial highlights show a decrease in cash from $166.1 million to $138.8 million and a net loss of $19.6 million for Q1 2024, unchanged from the previous year. R&D expenses dropped to $13.6 million, while G&A expenses rose to $7.9 million.